



140


**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

		Application Number	10/613,654
		Filing Date	July 3, 2003
		First Named Inventor	Keren et al.
		Art Unit	3763
		Examiner Name	Han, Mark K.
Total Number of Pages in This Submission		Attorney Docket Number	022352-000310US

ENCLOSURES (Check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard PTO Forms SB/08A and SB/08B Copies of 16 cited references	
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address		
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund		
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD		
<input type="checkbox"/> Certified Copy of Priority Document(s)		Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53			

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Townsend and Townsend and Crew LLP		
Signature			
Printed name	James M. Heslin		
Date	APRIL 14, 2005	Reg. No.	29,541

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Tiffany Wu	Date	4/15/05


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On 4/15/05

TOWNSEND and TOWNSEND and CREW LLP

By: Tiffany Wu



**PATENT**  
Attorney Docket No.: 022352-000310US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Keren et al.

Application No.: 10/613,654

Filed: July 3, 2003

For: APPARATUS AND METHODS  
FOR TREATING CONGESTIVE HEAR  
DISEASE

Examiner: Mark K. Han

Art Unit: 3763

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the Non-U.S. Patent references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Application No.: 10/613,654


Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



James M. Heslin  
Reg. No. 29,541

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
JMH:rlj  
60413295 v1



<p style="text-align: right;"><i>DEMAILED</i></p> <p>Institute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>		<i>Complete if Known</i>	
		Application Number	10/613,654
		Filing Date	July 3, 2003
		First Named Inventor	Keren et al.
		Art Unit	3763
		Examiner Name	Mark Han
		Attorney Docket Number	022352-000310US
Sheet	1	of	2

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>				
	6	WO	01/083016	4/27/2001	Keren et al.		<input type="checkbox"/>
	7	WO	01/41861	6/1/2001	Levin et al.		<input type="checkbox"/>
	8	WO	01/97687	12/27/2001	Levin et al.		
	9	WO	01/97717	12/27/2001	Levin et al.		
							<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (**optional**). Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet	2	of	2	Application Number	10/613,654
				Filing Date	July 3, 2003
				First Named Inventor	Keren et al.
				Art Unit	3763
				Examiner Name	Mark K. Han
				Attorney Docket Number	022352-000310US

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	10	AGOSTONI et al. Sustained Benefit from Ultrafiltration in Moderate Congestive heart failure Cardiology 2001:96 183-189		
	11	GRUBERG et al. The prognostic implications of further renal deterioration within 48 h of intervention etc. J AM Coll Cardiol 2000, 20(5):540-548		
	12	HALPENNY et al. The effects of fenoldopam on renal blood flow and tubular function during aortic cross-clamping in anaesthetized dogs, EUR J Anestheisol, 2000 Aug: 17(8); 491-8 Abstract		
	13	KINI et al. A protocol for Prevention of Radiographic contrast Nephropathy etc. Catheterization and Cardiovascular Interventions 2002, 55:169-173		
	14	KINI et al. Managing the High-Risk Patient: Experience with Fenoldopam etc. Rev. Cardiovas Med 2001:2(suppl 1) S19-S25		
	15	MADYOON, Use of Fenoldopam to Prevent Radiocontrast Nephropathy etc. Catheterization and Cardiovascular Interventions 2001, 53:341-345		
	16	MATHUR et al., The effects of fenoldopam, a selective dopamine receptor agonist, on renal hemodynamics etc. Abstract only. Crit Care Med Sep 1999: 27(9) 1832-1837		
	17	MULLER et al. Prevention of Contrast Media Associated Nephropathy, Arch Intern Med, Feb 2002, Vol. 162 pp. 329-336		
	18	NOHRIA et al. Medical Management of Advanced Heart Failure, JAMA, Feb. 6 2002, Vol. 283, pp. 628-640		
	19	TUMLIN et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion, AM heart J 2002; 894-903		
	20	UMRANI et al., Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats, Clin Exp Hypertens, 2002 Apr 24 (3): 207-19 Abstract only		
	21	ZACHERL et al. Periarterial Papaverine Applications Improves Intraoperative Kidney Function etc. Journal of Surgical Research 103:268-271 (2002)		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.